Toxic effects of fumonisin in mouse liver are independent of the peroxisome proliferator-activated receptor alpha.
Fumonisin mycotoxins occur worldwide in corn and corn-based foods. Fumonisin B1 (FB1) is a rodent liver carcinogen and suspected human carcinogen. It inhibits ceramide synthase and increases tissue sphinganine (Sa) and sphingosine (So) concentrations. Events linking disruption of sphingolipid metabolism and fumonisin toxicity are not fully understood; however, Sa and So were shown to bind mouse recombinant peroxisome proliferator-activated receptor alpha (PPARalpha) in vitro. To investigate the role of PPARalpha in fumonisin hepatotoxicity in vivo, wild-type (WT) and PPARalpha-null mice were fed control diets or diets containing 300 ppm FB1, Fusarium verticillioides culture material (CM) providing 300 ppm FB1, or 500 ppm of the peroxisome proliferator WY-14,643 (WY) for 1 week. WY-fed WT mice exhibited hepatomegaly, an effect not found in WY-fed PPARalpha-null mice, and WY did not change liver sphingoid base concentrations in either strain. Hepatotoxicity found in FB1- and CM-fed WT and PPARalpha-null mice was similar, qualitatively different from that found in WY-treated animals, and characterized by increased Sa concentration, apoptosis, and cell proliferation. Transcript profiling using oligonucleotide arrays showed that CM and FB1 elicited similar expression patterns of genes involved in cell proliferation, signal transduction, and glutathione metabolism that were different from that altered by WY. Real-time RT-PCR analysis of gene expression demonstrated PPARalpha-dependence of lipid metabolism gene expression in WY-treated mice, whereas PPARalpha-independent alterations of genes in lipid metabolism, and other categories, were found in CM- and FB1-fed mice. Together, these findings demonstrate that FB1- and CM-induced hepatotoxicity in mice does not require PPARalpha.
Voss
Kenneth A
KA
Toxicology & Mycotoxin Research Unit, USDA-Agricultural Research Service, Athens, Georgia 30604-5677, USA. kvoss@saa.ars.usda.gov
Liu
Jie
J
Anderson
Steven P
SP
Dunn
Corrie
C
Miller
J David
JD
Owen
Joy R
JR
Riley
Ronald T
RT
Bacon
Charles W
CW
Corton
J Christopher
JC
D000284:Administration, Oral; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002274:Carcinogens, Environmental / Q000633:toxicity*; D049109:Cell Proliferation / Q000187:drug effects; D017077:Culture Media, Conditioned / Q000493:pharmacokinetics; D004032:Diet; D005260:Female; D037341:Fumonisins / Q000633:toxicity*; D020869:Gene Expression Profiling; D006529:Hepatomegaly / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008815:Mice, Inbred Strains; D018345:Mice, Knockout; D009183:Mycotoxins / Q000633:toxicity*; D020411:Oligonucleotide Array Sequence Analysis; D047493:PPAR alpha / Q000235:genetics / Q000378:metabolism*; D020025:Peroxisome Proliferators / Q000633:toxicity; D011743:Pyrimidines / Q000633:toxicity; D013045:Species Specificity; D013110:Sphingosine / Q000031:analogs & derivatives / Q000378:metabolism
D002274:Carcinogens, Environmental; D017077:Culture Media, Conditioned; D037341:Fumonisins; D009183:Mycotoxins; D047493:PPAR alpha; D020025:Peroxisome Proliferators; D011743:Pyrimidines; C056933:fumonisin B1; C006253:pirinixic acid; D013110:Sphingosine; C005682:safingol